Skip to main content

Advertisement

Table 1 Baseline demographics and clinical characteristics (2014 cohort)

From: Evaluation of exacerbations and blood eosinophils in UK and US COPD populations

Characteristic CPRD database N = 15,364 Optum database N = 139,465
Age, years, mean (SD) 71.8 (10.4) 71.8 (10.6)
Gender
 Men 8,383 (54.6%) 71,417 (51.2%)
 Women 6,981 (45.4%) 68,047 (48.8%)
Charlson Comorbidity Indexa, median (IQR) 2.0 (1.0–4.0) 2.0 (0.0–3.0)
Baseline comorbidities common to COPD patientsb
 Hypertension 9,133 (59.4%) 106,687 (76.5%)
 Hyperlipidaemia 5,972 (38.9%) 91,779 (65.8%)
 Depression 5,321 (34.6%) 26,030 (18.7%)
 Anxiety 4,524 (29.4%) 23,138 (16.6%)
 Cancer 3,915 (25.5%) 32,729 (23.5%)
 Diabetes 2,755 (17.9%) 46,588 (33.4%)
Baseline medicationsc
 ICS 1,078 (7.0%) 5,900 (4.2%)
 LABA 513 (3.3%) 1,556 (1.1%)
 LAMA 3,658 (23.8%) 24,850 (17.8%)
 LAMA + LABA 423 (2.8%) 615 (0.4%)
 ICS + LABA 4,938 (32.1%) 29,763 (21.3%)
 ICS + LAMA + LABA 5,563 (36.2%) 10,490 (7.5%)
Smoking status
 Patients with smoking data reported, n 15,356
 Current smokers 4,996 (32.5%)
 Ex-smokers 9,499 (61.8%)
 Non-smokers 861 (5.6%)
GOLD classificationd
 Patients with GOLD assessment, n 6,029
 Group A 449 (7.4%)
 Group B 1,843 (30.6%)
 Group C 309 (5.1%)
 Group D 3,428 (56.9%)
mMRC dyspnoea scale
 Patients with mMRC data, n 10,899
 Grade 0 1,341 (12.3%)
 Grade 1 3,941 (36.2%)
 Grade 2 3,157 (29.0%)
 Grade 3 2,033 (18.7%)
 Grade 4 427 (3.9%)
Patients with FEV1 % predicted data 7,331 (47.7%)
 FEV1, % predicted, mean (SD) 61.6 (21.6)
Patients with FEV1/FVC data 6,769 (44.1%)
 FEV1/FVC, %, mean (SD) 60.2 (16.0)
  1. Data are presented as n (%), unless specified otherwise
  2. COPD chronic obstructive pulmonary disease, CPRD Clinical Practice Research Datalink, FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroid, IQR interquartile range, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, mMRC modified Medical Research Council, SD standard deviation
  3. aCharlson Comorbidity Index comprises 19 comorbid disease categories, each assigned a score from 1 to 6, and is used to predict 10-year mortality in patients with comorbidities; the greater the score, the greater the risk of mortality
  4. bComorbidities present in ≥ 25% of the patients in either database are presented
  5. cPatient was only counted if length of medication use was ≥ 30 days
  6. dAs per GOLD 2017 recommendations [10]